After kicking the tires on Autolus Therapeutics’ targeting technology, Moderna has decided to pay up for the right to use the binders in an mRNA therapy. The exercising of the option positions Moderna to use the binders in a candidate against an undisclosed immuno-oncology target. Source: Fierce Biotech 12/10/2022